Structural Features of Peptide Analogs of Human Histocompatibility Leukocyte Antigen Class I Epitopes that Are More Potent and Immunogenic than Wild-Type Peptide

Shabnam Tangri, Glenn Y. Ishioka, Xiuqing Huang, John Sidney, Scott Southwood, John Fikes, and Alessandro Sette

Epimmune Incorporated, San Diego, CA 92121

Abstract

Certain peptide analogs that carry substitutions at residues other than the main major histocompatibility complex anchors and are surprisingly much more antigenic than wild-type peptide (heteroclitic analogs). To date, it was unknown how frequently wild-type epitopes could be modified to obtain heteroclitic activity. In this study, we analyzed a large panel of analogs of two different human histocompatibility leukocyte antigen (HLA)-A2.1–restricted epitopes and found that heteroclitic analogs were associated with higher magnitude responses and increased (up to $10^7$-fold) sensitivity to antigen, and corresponded to conservative or semiconservative substitutions at odd-numbered positions in the middle of the peptide (positions 3, 5, or 7). These findings were validated by performing additional immunogenicity studies in murine and human systems with four additional epitopes. The biological relevance of heteroclitic analogs was underlined when predicted analogs of the p53.261 epitope was shown to induce cytotoxic T lymphocytes (CTLs) that recognize low concentrations of peptide (high avidity) in vivo and demonstrate in vitro antitumor recognition. Finally, in vitro immunization of human peripheral blood mononuclear cells with two heteroclitic analogs resulted in recruitment of more numerous CTLs which were associated with increased antigen sensitivity. In conclusion, heteroclitic analogs were identified in each of the six cases studied and structural features were defined which allow identification of such analogs. The strong CTL immunity elicited by heteroclitic epitopes suggest that they could be of significant value in vaccination against tolerant or weakly immunogenic tumor-associated and viral antigens.

Key words: heteroclitic analogs • CTL • MHC • amino acid substitutions • vaccine

Introduction

Several studies suggest that CTLs play a central role in the eradication of infectious disease and cancer by the immune system (1, 2). As CTLs recognize complexes of antigenic peptides and MHC, considerable effort is currently ongoing in developing epitope-based vaccines to stimulate CTL responses. Peptide analogs with increased binding affinity for their MHC restricting MHC molecule have been engineered by rational modification of the main MHC anchor residues. These “fixed anchor” analogs have been shown to be more antigenic and immunogenic in various experimental systems (3, 4). Normally, single substitution analogs of an antigenic peptide at positions other than the main MHC anchor residues would be expected to have either no effect or a detrimental effect on T cell activation. Certain analogs, however, have unexpectedly increased potency and these analogs are defined as “heteroclitic analogs,” as heteroclitic, according to the Webster’s dictionary (5), indicates “one that deviates from common norm.” These analogs may provide considerable benefit in vaccine development, as they induce stronger T cell responses than the native epitope (6, 7), and have been shown to be associated with increased affinity of the epitope/MHC complex for the TCR molecule (8). Advantages associated with using such analogs in clinical applications are as follows: (a) heteroclitic analogs have been shown to break/overcome tolerance by reversing a state of T cell anergy and/or recruiting new T cell specificities (9–11); (b) significantly smaller amounts of heteroclitic analogs may be needed for treatment (12); and (c) peptide analogs have previously been demonstrated to induce immune deviation by modulating cytokine production (13–15), which may have implications in several disease states.
where generation of a specific subset of Th cell response is required (16–18).

For the aforementioned reasons, it would be extremely useful to predict amino acid substitutions that render heteroclitic activity to a given antigenic peptide. To date, however, there is no easy method for predicting such substitutions. Indeed, in previous studies (19, 20) heteroclitic epitopes were fortuitously identified by eluting naturally occurring mutant peptides from melanoma cells or by systematically screening a large number of analogs and combinatorial libraries consisting of substitutions at almost every position in the epitope (6, 7, 21, 22). Genetic approaches, such as screening of DNA expression libraries, have provided another method for generating CTL epitopes and analogs (23, 24). However, this approach may be problematic given the potentially small quantities and complexity of epitopes generated.

In this study we examined whether heteroclitic analogs could be consistently identified for several different CTL epitopes, or only for relatively rare occurrences. Furthermore, we sought to understand the structural features associated with heteroclicity, thereby circumventing the need to employ time-consuming analogue screening methods for identification of heteroclitic analogs.

Materials and Methods
Peptide Synthesis and Generation of Peptide Analogs. Peptides used in this study are shown in Table I. All of the human CTL epitopes that were derived from tumor-associated and viral antigens have been described in previous studies where their immunogenicity in human and transgenic mouse systems was demonstrated (25, 26).

Large collections of peptides tested for heteroclitic activity were synthesized by Chiron Corp. as crude material. Further biological characterizations were performed with peptides synthesized and purified (>95% purity) at Epimmune using described methods (27), and their identity was confirmed by mass spectral analysis before use.

Scheme for Selection of Single Amino Acid Substitutions. The degree of similarity between amino acid pairs was quantified by averaging, for each amino acid pair, the rank coefficient scores for PAM250, hydrophobicity, and side chain volume (see below). Based on the average values of these composite rankings, shown in Fig. 1, similarity assignments between any given amino acid pair was derived so that a given amino acid substitution could be characterized as being a conservative, semiconservative, or nonconservative substitution.

The Dayhoff PAM250 score (28, 29; http://prowl.rockefeller.edu/aainfo/pam250.html) is a commonly used protein alignment scoring matrix which measures the percentage of acceptable point mutations within a defined time frame. The frequencies of these mutations are different from what would be expected from the probability of random mutations, and presumably reflect a bias due to the degree of physical and chemical similarity of the amino acid pair involved in the substitution. To obtain a score of amino acid similarity that could be standardized with other measures of similarity, the PAM250 scores were converted to a rank value, where 1 indicates the highest probability of being an accepted mutation.

The most commonly used scales to represent the relative hydrophobicity of the 20 naturally occurring amino acids (30) are those developed on the basis of experimental data by Kyte and Doolittle (31), and by Fauchere and Plisca (32). The Kyte/Doolittle scale measures the H2O/O/organic solvent partition of individual amino acids. Because it considers the position of amino acids in folded proteins, it may most accurately reflect native hydrophobicity in the context of proteins. The Fauchere/Plisca scale measures the octanol/H2O partitioning of N-acetyl amino acid amides, and most accurately reflects hydrophobicity in the context of denatured proteins and/or small synthetic peptides. To obtain scores for hydrophobicity, each amino acid residue was ranked on both the Kyte/Doolittle and Fauchere/Plisca hydrophobicity scales. An average rank between the two scales was calculated and the average difference in hydrophobicity for each pair was calculated.

Finally, for calculating amino acid side-chain volume, the partial volume in solution obtained by noting the increase in volume of water after adding either one molecule or 1 g of amino acid residue was considered (33, 34). The absolute difference in the partial volume of each possible pairing of the 20 naturally occurring amino acids was calculated and ranked, where 1 indicated residues with the most similar volumes, and 20 the most dissimilar.

Measurement of Peptide Binding Affinity for the HLA-A2.1 Molecule. Binding of test peptides to HLA-A2.1 was measured by determining the level of competition induced by the test peptide for binding of a radiolabeled standard peptide to purified HLA-A2.1 molecules. The percentage of MHC-bound radioactivity was determined by gel filtration and the concentration of test peptide that inhibited 50% of the binding of the labeled standard peptide (IC50%) was calculated (27, 35). The standard peptide was the hepatitis B virus (HBV)* Core:18-epitope (sequence FLPSDFFPSV).

Mice. HLA-A2.1/Kb* and HLA-A2.1/Kb× transgenic mice were bred at Epimmune. These strains represent the F1 generation of a cross between an HLA-A2.1/Kb× transgenic strain generated on the C57BL/6 background (36) and SJL or BALB/c mice (The Jackson Laboratory), respectively.

APC Lines. The .221A2.1 cell line was generated by transfecting the HLA-A2.1 gene into the HLA-A,-B,-C-null mutant EBV-transformed human B-lymphoblastoid cell line 3A4–721.221 (25). Jurkat cells and methylcholanthrene-induced sarcoma tumor cells (Meth A) were transfected with the HLA-A2.1 or A2.1/Kb molecule as described (26, 36). The carcinoma-oncogenic antigen (CEA)—expressing colon adenocarcinoma lines SW403 (A2+, CEA+) and HT29 (A2-, CEA+) were obtained from the American Tissue Type Collection. The tumor cell lines were treated with 100 IU/ml human IFN-γ (Genzyme) for 48 h at 37°C before using as APCs. All cells were grown in RPMI-1640 supplemented with antibiotics, sodium pyruvate, nonessential amino acids, and 10% FBS.

Primary In Vitro Induction of CTLs from PBMCs and Derivation of Human CTL Lines. To generate peptide-specific CTL lines against the CEA.691 epitope and to examine the immunogenicity of CEA.691 analogs, PBMCs from normal subjects were stimulated repeatedly with peptide in vitro in 48-well plates (25). To check CTL activity after two rounds of stimulation, PBMCs from each culture (well) were cultured with .221-A2.1 APC in the presence or absence of peptide or, in some experiments, with

*Abbreviations used in this paper: CEA, carcinoembryonic antigen; HBV, hepatitis B virus; ELISPOT, enzyme-linked immunospot.
tumor cells that endogenously express the wild-type epitope. Cultures were scored positive for CTL induction if the net IFN-γ production was >100 pg/well and IFN-γ production in the presence of peptide was at least twofold above background.

**Murine CTL Lines.** CTL lines against epitopes HBV Pol.455 and HIV Pol.476 peptides were generated in HLA-A2.1/Kbxs transgenic mice by DNA immunization (26). Similarly, a CTL line against the MAGEA2.157 epitope was generated by immunizing HLA-A2.1/Kbxs mice subcutaneously at the tail base with 50 µg of peptide and 140 µg of the HBV Core.128 Th epitope (TPPAYRPPNAPIL), emulsified in IFA and restimulating primed splenocytes repeatedly in vitro (26).

**Measurement of Murine and Human IFN-γ, IL-5, and IL-10 Production by CTLs.** An in situ capture ELISA was used for measuring IFN-γ release from mouse or human CTL (37). Anti–mouse or anti–human IFN-γ mAb for this assay were purchased from BD PharMingen. Murine and human IL-5 and IL-10 was measured in culture supernates using ELISA kits (R&D Systems).

**Enzyme-linked Immunospot Assay for Measuring Ex Vivo Murine CTL Responses.** Enzyme-linked immunospot assay (ELISPOT) assays were performed according to standard protocols (38, 39). Briefly, 4 × 10^6 splenic CD8<sup>+</sup> cells isolated by magnetic beads (Miltenyi Biotec) and 5 × 10^6 Jurkat-A2.1/K<sub>b</sub> cells pulsed with 10 µg/ml of peptide were cultured in flat-bottom 96-well nitrocellulose plates (Imnobilon-P membrane; Millipore) which had been pre-coated with anti–IFN-γ mAb (BD PharMingen; 10 µg/ml). After 24 h incubation at 37°C, plates were washed with PBS/0.05% Tween and wells were incubated with a biotinylated anti–IFN-γ mAb (BD PharMingen; 2 µg/ml) for 4 h at 37°C. After additional washing, spots were developed by sequential incubation with Vectastain ABC peroxidase (Vector Laboratories) and 3-amino-9-ethyl carbazole (AEC) solution (Sigma-Aldrich) and counted by computer-assisted image analysis (ZEISS KS ELISPOT Reader). The net number of spots/10<sup>6</sup> CD8<sup>+</sup> cells was calculated as follows: (number of spots against relevant peptide)/number of spots against irrelevant control peptide) - 2.5.

**Figure 1.**

| M | N | P | Q | R | S | T | V | W | Y |
|---|---|---|---|---|---|---|---|---|---|
| 1.0 | 1.0 | P | 1.0 | Q | 1.0 | R | 1.0 | S | 1.0 |
| L | 1.0 | D | 1.0 | T | 1.0 | E | 1.0 | F | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| A | 1.0 | C | 1.0 | D | 1.0 | E | 1.0 | F | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| S | 1.0 | V | 1.0 | T | 1.0 | E | 1.0 | F | 1.0 |
| T | 1.0 | E | 1.0 | F | 1.0 | G | 1.0 | H | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| A | 1.0 | C | 1.0 | D | 1.0 | E | 1.0 | F | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| S | 1.0 | V | 1.0 | T | 1.0 | E | 1.0 | F | 1.0 |
| T | 1.0 | E | 1.0 | F | 1.0 | G | 1.0 | H | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| A | 1.0 | C | 1.0 | D | 1.0 | E | 1.0 | F | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| S | 1.0 | V | 1.0 | T | 1.0 | E | 1.0 | F | 1.0 |
| T | 1.0 | E | 1.0 | F | 1.0 | G | 1.0 | H | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| A | 1.0 | C | 1.0 | D | 1.0 | E | 1.0 | F | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| S | 1.0 | V | 1.0 | T | 1.0 | E | 1.0 | F | 1.0 |
| T | 1.0 | E | 1.0 | F | 1.0 | G | 1.0 | H | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| A | 1.0 | C | 1.0 | D | 1.0 | E | 1.0 | F | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| S | 1.0 | V | 1.0 | T | 1.0 | E | 1.0 | F | 1.0 |
| T | 1.0 | E | 1.0 | F | 1.0 | G | 1.0 | H | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| A | 1.0 | C | 1.0 | D | 1.0 | E | 1.0 | F | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| S | 1.0 | V | 1.0 | T | 1.0 | E | 1.0 | F | 1.0 |
| T | 1.0 | E | 1.0 | F | 1.0 | G | 1.0 | H | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| A | 1.0 | C | 1.0 | D | 1.0 | E | 1.0 | F | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| S | 1.0 | V | 1.0 | T | 1.0 | E | 1.0 | F | 1.0 |
| T | 1.0 | E | 1.0 | F | 1.0 | G | 1.0 | H | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| A | 1.0 | C | 1.0 | D | 1.0 | E | 1.0 | F | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| S | 1.0 | V | 1.0 | T | 1.0 | E | 1.0 | F | 1.0 |
| T | 1.0 | E | 1.0 | F | 1.0 | G | 1.0 | H | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| A | 1.0 | C | 1.0 | D | 1.0 | E | 1.0 | F | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| S | 1.0 | V | 1.0 | T | 1.0 | E | 1.0 | F | 1.0 |
| T | 1.0 | E | 1.0 | F | 1.0 | G | 1.0 | H | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| A | 1.0 | C | 1.0 | D | 1.0 | E | 1.0 | F | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| S | 1.0 | V | 1.0 | T | 1.0 | E | 1.0 | F | 1.0 |
| T | 1.0 | E | 1.0 | F | 1.0 | G | 1.0 | H | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| A | 1.0 | C | 1.0 | D | 1.0 | E | 1.0 | F | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| S | 1.0 | V | 1.0 | T | 1.0 | E | 1.0 | F | 1.0 |
| T | 1.0 | E | 1.0 | F | 1.0 | G | 1.0 | H | 1.0 |
| G | 1.0 | H | 1.0 | I | 1.0 | K | 1.0 | L | 1.0 |
| A | 1.0 | C | 1.0 | D | 1.0 | E | 1.0 | F | 1.0 |

* Values represent the average similarity score on a 3-point scale: 1, PAD250 matrix; 2, difference in average tandem repeats; 3, difference in side chains volume.
Screening of Peptide Analogs for Heteroclitic Activity. Prior to screening analogs, 221A2.1 tumor cells (10^5 cells/well) pulsed with varying doses of peptide were cultured with an equivalent number of murine or human CTLs. The level of IFN-γ released by CTLs was measured by the in situ capture ELISA assay after 24 h (murine) or 48 h (human) of incubation at 37°C. After determining a titration curve, a suboptimal peptide dose was selected for each CTL line where activity against wild-type peptide was barely detectable. This dose was typically in the range of 0.1–1 μg/ml. For screening of peptide analogs, 221A2.1 cells were pulsed with each analogue at the selected suboptimal dose and peptide-loaded APCs were cultured with CTLs as described above. Analogos inducing enhanced CTL responses relative to wild-type peptide were then selected for further characterization. These analogs were tested side-by-side with the wild-type epitope in a peptide dose titration under identical conditions described above. It should be noted that although murine CTL lines were generated in HLA-A2.1/K^b transgenic mice which express an HLA molecule with murine H-2Kb sequences in the third domain, all lines responded to peptide presented on APCs expressing the native HLA-A2.1 molecule.

In Vivo Immunogenicity of Predicted p53.261 Analogs in HLA-A2.1/K^b2 Transgenic Mice. Immunogenicity for the murine p53.261 predicted analogs were tested in HLA-A2.1/K^b2 transgenic mice by co-immunizing mice with 50 μg of the p53.261 epitope (LLGRDSFEV) or its predicted analogs and 140 μg of the HBV Core.128 Th epitope in IFA. Splenocytes from analogue-primed animals were stimulated twice in vitro with either the respective immunizing analogue (to determine avidity and precursor frequency of CTLs responding to the analogue) or the wild-type peptide (to determine the cross-reactivity, avidity, and precursor frequency of CTLs that respond to wild-type antigen). Splenocytes from wild-type peptide-immunized animals were stimulated and tested against wild-type peptide. All short-term, bulk populations of CTL were tested for peptide specificity by the IFN-γ in situ ELISA 5 d after the second in vitro stimulation, using Jurkat-A2.1 as APC. Alternatively, CTL responses were performed on freshly isolated spleen cells from immunized animals using the ELISPOT assay.

Results

Identification of CEA.691 and MAGEA3.112 Analogs Associated with Increased IFN-γ Release. To identify heteroclitic analogs, a total of 117 CEA.691 and 116 MAGEA3.112 analogs of the CEA.691 and MAGEA3.112 epitopes were generated by systematically replacing each residue with 17 different single amino acids. The residues Cys, Trp, and Met were in general avoided unless they corresponded to conservative changes. Substitutions were introduced at all positions in the peptide except at positions 2 and the COOH termini, the main MHC anchor positions for HLA-A2. These analogs were then tested in vitro for their antigenicity against polyclonal CTL lines specific for MAGEA3.112 and CEA.691 epitopes. It should be emphasized that polyclonal rather than clonal populations of T cells were used in the study. Our objective was to define patterns associated with heterocliticity that encompass multiple TCR families found in a polyclonal population, to avoid any potential bias introduced by examination of CTL clones expressing only a single TCR clonotype.

Preliminary dose titration experiments for each CTL line defined a suboptimal concentration of wild-type peptide (data not shown). This suboptimal concentration was then used for subsequent antigenicity assays of analogue peptides for each epitope, so that analogs associated with increased T cell stimulatory capacity could be identified. Results of such antigenicity analysis for the CEA.691 analogs are shown in Fig. 2A. At the suboptimal 100 ng/ml dose the wild-type CEA.691 peptide induced only marginal IFN-γ production (<50 pg/well). By contrast, at the same dose, several CEA.691 analogs (M3, L4, P4, H5, L5, H6, T6, and 17) induced detectable levels of IFN-γ production in the 125 to 350 pg/well range. Similarly, for the MAGEA3.112-specific CTL line 100 ng/ml of wild-type peptide induced the release of 100 pg/ml of IFN-γ, whereas two analogs (15 and W7) were associated with inducing IFN-γ levels of over 300 pg/well (Fig. 2B).

All analogs of both CEA.691 and MAGEA3.112 that stimulated IFN-γ above 100 pg/well were chosen for further characterization and a complete dose titration was performed to identify heteroclitic analogs. Herein, heteroclitic analogs are considered as those which stimulate significant IFN-γ release (>100 pg/well) at 10-fold or lower peptide concentrations than wild-type peptide. A 100 pg/well cutoff was selected, as it represented a level of IFN-γ that was threefold above background, based on analysis of various CTL lines in several independent experiments.

Dose titration analysis for the CEA.691 analogs resulted in the identification of two heteroclitic analogs, namely M3 and H5. As seen in Fig. 2C, the wild-type CEA.691 peptide yielded a significant detectable IFN-γ signal in the 1 to 10 μg/ml dose range while the analogs M3 and H5 stimulated significant release with as little as 0.01 ng/ml and 0.1 pg/ml of peptide, respectively. The I7 analogue, which appeared to be heteroclitic in initial screening assays (Fig. 2A), failed to demonstrate heteroclitic activity upon further testing.

Similar dose titration analysis for the MAGEA3.112 epitope resulted in the identification of two heteroclitic analogs, I5 and W7. As shown in Fig. 2D, 1 μg/ml of wild-type peptide was required for significant IFN-γ release whereas ~0.1 ng/ml of analogue I5 or 0.1 pg/ml of analogue W7 was required to stimulate an equivalent response. It should be pointed out that, in general, the heteroclitic analogs not only induced a dose response shift, but they also stimulated CTLs to produce higher levels of IFN-γ compared with wild-type peptide.

Distinct Structural Features Associated with Heteroclitic Substitutions. The identification of four heteroclitic analogs described above suggested that certain properties might be associated with heteroclitic substitutions. Specifically, amino acid substitutions were conservative or semiconservative in nature, as defined by our scheme for assigning conservancy of single amino acid substitutions (see Materials and Methods). It should be noted that the similarities between amino acids according to this scheme are not always bidirectional. This may appear counterintuitive or even confusing at first, but it is a general feature of ranking of amino acid replace-
ments which take into account similarities and replacement rates. For example, substituting an average size residue glutamine (Q) with either a small residue such as glycine (G) or a large one such as tryptophan (W) will rank as an extreme substitution in terms of size. By contrast, substituting the same small size residue (G) with an average size residue (Q) will rank only as average while the (W) substitution will rank as extreme in terms of size replacements. In

Figure 2. Antigenicity of CEA.691 or MAGEA3.112 analogs tested with CTLs specific for wild-type (WT) epitope. IFN-γ produced by CEA.691-specific CTLs (A) or MAGEA3.112-specific CTLs (B) was measured after stimulation with analogue peptides. The position number of the amino acid that was substituted appears at the top of each graph and the native residue corresponding that position is shown along the X-axis. Each bar represents the CTL response stimulated by each analogue. The amino acid substitution of analogs that were further characterized for heteroclitic activity in a dose titration is indicated next to the corresponding response and the CTL response against heteroclitic analogs of CEA.691 (C) and MAGEA3.112 (D) compared with WT is shown. Significant production of IFN-γ was considered to be levels >100 pg/well (dotted lines). Background IFN-γ release by CTL stimulated by unpulsed target cells ranged between 25–40 pg/well.
addition, Dayhoff replacement frequencies tabulate substitutions which conserve biological function and these substitutions are also not always bidirectional. For example a tryptophan can be substituted by a positively charged (K) without drastic effect, while substituting a lysine (K) engaged in a salt bridge with tryptophan may lead to total loss of biological function.

Furthermore, substitutions tended to be at odd-numbered positions (position 3, 5, or 7) in the center of the peptide (Table I). To test whether conservative or semi-conservative substitutions at odd-numbered positions in the middle of an epitope are indeed associated with heteroclicity, three additional A2.1-restricted epitopes, the MAGEA2.157 tumor epitope and two epitopes from viral antigens, HBV Pol.455 and HIV Pol.476, were analyzed. All three epitopes have been shown to be immunogenic for CTLs in earlier studies (25, 26, 40).

For this purpose a panel of 212 different analogs was synthesized. These analogs included five conservative and five nonconservative amino acid substitutions at predicted positions (3, 5, or 7) as well as at irrelevant positions (1, 4, 6, or 8). Due to the technical ease associated with generating and maintaining murine CTL lines, analogs were tested for heteroclicity using CTL lines generated in HLA-A2.1/Kbxs transgenic mice, following an experimental strategy similar to the one described above.

Antigenicity analysis of the MAGEA2.157 analogs is depicted in Fig. 3 A, where analogs inducing IFN-γ production in excess of 500 pg/well (specifically F1, H3, K3, E3, N3, I5, F5, T5, Y5, N7, and M8) were characterized further in a dose titration analysis. From a total of 77 different analogs tested two heteroclitic analogs were identified, F5 and I5, that stimulated IFN-γ responses at 100- to 10,000-fold lower doses than wild-type peptide (Table I). As before, both of these analogs had substitutions that were conservative or semiconservative in nature occurring at an odd-numbered position in the center of the peptide (position 5). Antigenicity analysis of analogs for two other epitopes, HBV Pol.455 and HIV Pol.476, are shown in Fig. 3, B and C, respectively. Further characterization of the HBV Pol.455 epitope, out of 66 initially tested that had a conservative substitution at position 7 (Table I). For the HIV Pol.476 epitope, out of 69 different analogs initially screened in Fig. 3 C, two analogs were identified as having heteroclitic activity (H3 and L3; Table I). Once again, both analogs carried either a conservative or semi-

| Antigen | Sequence | Heteroclitic substitution | Type of substitution | Position of substitution | Th1 cytokines | Th2 cytokines | A*0201 binding (IC50 nM) |
|---------|----------|---------------------------|---------------------|-------------------------|---------------|---------------|--------------------------|
| CEA.691 | IMIGVLGV | None (WT)                 | None                | 1                       | 10            | 54            |                          |
| CEA.691M3 | IMMGVLGV | I→M                       | Conservative        | 3                       | 10⁻⁵         | 1             | 27                       |
| CEA.691H5 | IMIGHLVGV | V→H                       | Semiconservative    | 5                       | 10⁻⁷         | 10⁻¹         | 16                       |
| MAGEA3.112 | KVABLVHFL | None (WT)                 | None                | 1                       | NS⁴          | 94            |                          |
| MAGEA3.112I5 | KVABIVHFL | L→I                       | Conservative        | 5                       | 10⁻⁴         | NS            | 66                       |
| MAGEA3.112W7 | KVABLVWF | H→W                       | Semiconservative    | 7                       | 10⁻⁷         | NS            | 7                        |
| MAGEA2.157 | YLQLVFGIEV | None (WT)               | None                | 1                       | 10           | 40            |                          |
| MAGEA2.157I5 | YLQLIFGIEV | V→I                       | Conservative        | 5                       | 10⁻⁴         | 10⁻²         | 476                      |
| MAGEA2.157F5 | YLQLFGIEV | V→F                       | Semiconservative    | 5                       | 10⁻²         | 10⁻²         | 212                      |
| HBV Pol.455 | GLSRYVARL | None (WT)                  |                     | 10                      | 10           | 83            |                          |
| HBV Pol.455P7 | GLSRYVFR | A→P                       | Conservative        | 7                       | 10⁻²         | 10⁻²         | 267                      |
| HIV Pol.476 | ILKEPVHGV | None (WT)                 |                     | >10                     | >10          | 369           |                          |
| HIV Pol.476H3 | ILHEPVHGV | K→H                       | Conservative        | 3                       | 1            | 1             | 78                       |
| HIV Pol.476L3 | ILEPFVHGV | K→L                       | Semiconservative    | 3                       | 10⁻¹         | 1             | 63                       |

WT, wild-type.

aMinimum peptide concentration (µg/ml) required to induce 100 pg/well of IFN-γ (Th1 cytokines).
bMinimum peptide concentration (µg/ml) required to induce 50 pg/well of IL-10 or IL-5 (Th2 cytokines).
cA relative binding change of fourfold or more compared to wild-type peptide is considered significant and is indicated in bold.

bNS indicates levels of cytokines <5 pg/ml.
conservative substitution at an odd-numbered position in the center of the peptide.

In summary, analysis of data obtained from this second study, consisting of 212 analogs for three additional epitopes of tumor and viral origin were consistent with our previous analysis of the MAGEA3.112 and CEA.691 epitopes. These data validated our earlier patterns identified for heteroclitic substitutions inasmuch as all five of the heteroclitic analogs identified in the second study had substitutions that were of conservative or semiconservative nature, and in all cases substitutions occurred at odd-numbered positions (3, 5, or 7) in the middle of the peptide.

Lymphokine Profile Induced by Heteroclitic Analogs. Heteroclitic analogs have been shown previously to differentially activate cytokine production from T cells such that some analogs specifically activate Th1 cytokine production while others preferentially activate production of Th2 cytokines (13, 14). To investigate the cytokine pattern associated with the heteroclitic analogs, the production of the Th2 cytokines IL-5 and/or IL-10 from CTL lines was compared with the production of a Th1 cytokine IFN-γ. Representative data is shown in Fig. 4. The F5 and I5 analogs of MAGEA2.157 induced significant levels of IFN-γ production at 100-fold or 10,000-fold lower concentrations than wild-type peptide, respectively (Fig. 4 A). Moreover, the same analogs also induced significant IL-10 production at a 100-fold lower peptide concentration than wild-type peptide (Fig. 4 B).

HLA-A2.1 Binding Affinity of Heteroclitic Analogs. In the course of the studies described above the MHC contact residues were not intentionally substituted. However, we wished to verify that the enhanced recognition by CTL lines observed was not due to a fortuitous increase in MHC binding capacity of the analogue epitope. The MHC binding affinity of all heteroclitic analogs was therefore measured and compared with their unmodified wild-type counterparts. As summarized in Table I, three analogs bound to HLA-A2.1 with fourfold or higher affinity than wild-type peptide (MAGEA3.112W7, HIV Pol.476H3, and HIV Pol.476L3) and two analogs bound with lower affinity (MAGEA2.157I5, MAGEA2.157F5). The four remaining heteroclitic analogs, MAGEA3.112I5,

Figure 3. Antigenicity of analogs from three additional epitopes of tumor and viral antigens. IFN-γ production by CTLs specific for MAGEA2.157 (A), HBV Pol.455 (B), and HIV Pol.476 (C) in response to analogue-pulsed or wild-type (WT)-pulsed .221A2.1 cells is shown. The dotted line at each position demarcates the groups of five analogs with conservative/semiconservative substitutions (left of the line) and nonconservative substitutions (right of the line). Background IFN-γ responses were <25 pg/well.
CEA.691M3, CEA.691H5, and HBV Pol.455P7, were associated with little or no change in HLA-A2.1 binding capacity. This lack of correlation between changes in HLA binding and heteroclicity suggests that heteroclicity is not mediated by an increase in MHC binding affinity, unlike the increased T cell responses resulting from substitutions of MHC anchor residues (41, 42). Our studies, however, do not exclude the possibility that alterations in MHC binding affinity might indirectly affect T cell recognition through the introduction of subtle structural modifications in the peptide regions recognized by the TCR. Minor structural modifications, not unlike what we are proposing for heteroclitic analogs, have been previously reported to affect TCR recognition and generate antagonist or agonist peptides (43, 44).

**Prediction and Immunogenicity of Analogs for the Murine p53.261 Epitope.** To further validate the heteroclitic substitution rules, we performed additional studies where heteroclitic analogs were predicted according to the structural features described above and then tested for their immunogenicity in vivo. For these studies, the HLA-A2.1–restricted murine p53.261 epitope was selected, as CTL responses against this epitope have been shown to be partially tolerized in HLA-A2.1/Kb transgenic mice (45, 46), thus allowing the opportunity to analyze the capacity of predicted heteroclitic analogs to increase CTL responses against an epitope that is weakly immunogenic in vivo.

A panel of nine analogs of the p53.261 epitope consisting of three conservative or semiconservative substitutions at positions 3, 5, and 7 of the nonamer peptide was tested for immunogenicity in HLA-A2.1/Kb transgenic mice. Immunization of mice with each of the nine analogs resulted in identification of three analogs (D3, H3, L7) that gave CTL responses characterized by IFN-γ production of 100 pg/well at lower peptide concentrations compared with CTLs induced with wild-type peptide (Fig. 5 A). These results indicate that a significant percentage (33%) of
the predicted analogs induce CTLs of a higher avidity than those induced by wild-type peptide itself.

The cross-reactivity of CTLs primed with these heteroclitic analogs with wild-type peptide is shown in Fig. 5 B. CTLs obtained from animals immunized and restimulated with wild-type peptide induced 100 pg/well IFN-γ at peptide doses between 1–10 μg/ml. In contrast, CTLs obtained from animals immunized with analogs L7, H3, and D3 that were stimulated and tested in vitro with wild-type peptide required lower doses of wild-type peptide to induce 100 pg/well of IFN-γ in the range of 0.2 to 0.001 μg/ml (Fig. 5 B). Thus, in three out of nine cases the predicted heteroclitic analogs induced CTL in vivo which were 10- to a 1,000-fold more active/potent against a weakly immunogenic wild-type peptide compared with wild-type–induced CTL. Although the heterocritic properties of the L7 analogue appear marginal in Fig. 5 B, data from precursor frequency analysis, described below, confirmed its heterocicity. The biological relevance of the analogue-induced CTL responses was underlined when a p53<sup>+</sup> Meth A–transformed tumor cell clone, transfected with HLA-A2.1/K<sup>E</sup>, was used as APC. Significantly greater production of IFN-γ was observed when analogue-induced CTL were stimulated with the endogenously-processed wild-type epitope expressed by the HLA-A2.1/K<sup>E</sup> Meth A tumor clone compared with CTLs generated by the wild-type peptide (Fig. 6).

**Precursor Frequency Analysis Using the ELISPOT Assay.** To determine the frequencies of wild-type–reactive CTLs, splenic CD8<sup>+</sup> cells were isolated from mice immunized with heteroclitic analogs or wild-type peptide and tested for reactivity against the wild-type peptide using an ELISPOT assay without any prior CTL expansion in vitro. As shown in Fig. 7, immunization with the heteroclitic p53.261 analogs D3, H3, and L7 induced a significantly higher level of CTL effectors responding to the wild-type epitope (CTL frequency of ~1/15,000, or 60–75 spots/10<sup>6</sup> cells), compared with immunization with wild-type epitope (frequency of 1/67,000 or 15 spots/10<sup>6</sup> cells).

**Heteroclitic Analogs Induce Human CTLs Capable of Recognizing Tumor Cells In Vitro.** To further underline the physiologic relevance of our observations, we examined whether heteroclitic analogs of the CEA.691 epitope could induce human CTLs in a primary in vitro induction system. Fresh naive human PBMC from normal donors were stimulated repetitively in vitro with either the wild-type CEA.691 epitope or the M3 and H5 analogs. A higher number of CTL-positive cultures was detected when PBMCs were stimulated with two of the heteroclitic CEA analogs (Fig. 8, B and C) compared with the wild-type epitope (Fig. 8 A; 11 positive/48 total wells for the M3 analogue and 10/48 for the H5 analogue versus 2/48 for wild-type). More importantly, a higher frequency of analogue-induced CTL cultures recognized the naturally processed form of the wild-type epitope (9 positive/48 total wells for both analogs, versus 2/48 for wild-type immunogen; P value < 0.02). Only CTLs from cultures that displayed peptide specificity also recognized endogenous epitope-expressing tumor cells indicating that the latter reactivity was epitope-specific.

Avidity analysis of peptide-reactive CTL cultures from the above experiment was performed by restimulating a small number of cultures one additional time in vitro. When tested against 221A2.1 cells pulsed with different concentrations of wild-type peptide, CTLs induced with the CEA analogs H5 and M3 demonstrated higher avidity
than those induced with wild-type peptide (Fig. 8 D), in keeping with our results with the murine p53.261 epitope. Moreover, we determined the number of wild-type reactive cells using an ELISPOT assay for these indicated wells to substantiate the findings that the higher avidity of these cultures is not a result of greater number of wild-type specific CTLs present in cultures induced in vitro with analogue peptides. As indicated in the Fig. 8 D, the number of wild-type reactive cells in well #4 (induced with wild-type peptide) was $3,060/10^6$ (0.3%) whereas in case of well #42 (induced with analogue M3) and well #44 (induced with analogue H5) the number of wild-type reactive cells were $1,420/10^6$ (0.14%) and $1,360/10^6$ (0.14%), respectively. This indicates that the CTL cultures induced by analogs...
did indeed recognize lower concentrations of wild-type peptide (higher avidity) and the effect was not do to greater numbers of wild-type reactive cells present in the analogue induced cultures. In summary, our results demonstrate that heteroclitic analogs can induce high avidity, physiologically relevant human CTLs that recognize endogenously generated wild-type peptide presented by tumor cells and that the analogs identified by the heteroclitic substitution patterns are relevant in both human and transgenic mouse systems.

Discussion

In this study, we report the identification of heteroclitic analogs of five different HLA-A2.1-restricted CTL epitopes of cancer and viral origin, that were characterized as CTL epitopes in our previous studies and from other studies reported in the literature (25, 26, 40). In initial experiments for this study, the antigenicity of 233 analogs of the CEA.691 and MAGEA3.112 CTL epitopes was investigated to determine the commonality of heteroclitic analogs and to identify patterns of heteroclitic substitutions. The nature of the four heteroclitic analogs identified suggested that heteroclitic substitutions tended to involve conservative/semiconservative substitutions at odd-numbered positions in the center of the peptide. This hypothesis was tested in a subsequent study involving three additional well-characterized epitopes, MAGEA2.157, HIV Pol.476, and HBV Pol.455. All of the heteroclitic analogs identified in this study followed the previously observed pattern of conservative or semiconservative substitutions at odd-numbered positions.

To more closely mimic the clinical application of heteroclitic analogs in cancer immunotherapy, the murine epitope p53.261, for which a partial state of T cell tolerance has been reported previously in HLA-A2.1/Kb transgenic mice, was selected (45, 46). Out of a panel of nine predicted analogs, three p53.261 analogs induced CTLs which responded vigorously against the native p53.261 epitope. Finally, the relevance of these findings for human CTLs was addressed by demonstrating that heteroclitic analogs of the CEA.691 epitope are immunogenic for human T cells in vitro. The CTLs induced by primary in vitro induction with analogs were able to recognize the naturally processed wild-type epitope expressed on tumor cell lines. These studies therefore suggest that heteroclitic analogs are significantly better at inducing immune responses than wild-type antigen and could offer substantial improvements in the design of epitope-based vaccines.

Our studies demonstrate that heteroclicity is a fairly common phenomenon as heteroclitic analogs were identified for all six epitopes studied. In addition, we have shown that it is possible to detect heteroclitic analogs using bulk T cell populations, not unlike studies from other laboratories that have used more clonal T cell populations. In this study we intended to avoid the limitation of focusing heteroclitic peptide identification to epitopes recognized by single CTL clones and for this reason bulk CTL lines were used. However, in future studies it will be interesting to formally prove that the selected peptide analogs do have heteroclitic activity for a broad range of CTL clones directed against the same nominal peptide antigen.

Finally, we have demonstrated that heteroclicity (at least in the HLA-A2.1 system) is associated with discrete structural features which allow rational prediction of heteroclicity. Our method involved developing a composite value based on a protein alignment scoring matrix, two hydrophobicity rankings, and a measurement of side chain volume derived from the partial specific volume of each amino acid. The ranking produced some unexpected similarities. For example, substitutions like A-P, G-D, H-E, G-P, and S-P might be somewhat unanticipated as conservative shifts. However, based on our results, development of an objective ranking scheme appears to constitute a much improved approach to identifying altered peptide ligands with heteroclitic activity. The first feature associated with heteroclitic effects for HLA-A2.1 epitopes was the occurrence of conservative or semiconservative substitutions at odd-numbered positions (3, 5, or 7) in the middle of the peptide. While heteroclicity is ultimately dependent on the orientation of specific side chains of the analogue in the structure of the trimeric complex (TCR-MHC-peptide), insertion of substitutions at odd-numbered positions can provide an empirical guide for the identification of heteroclitic analogs that enhance T cell activation. In these positions we frequently observed either a positive or a negative alteration in MHC binding, and some of these positions, particularly 3, 7, and in some cases position 5 have been shown to be secondary anchor positions for binding to the HLA-A2.1 molecule (27, 47–48). Moreover, these positions have less frequently been identified as TCR contact positions by crystallization studies of HLA-A2.1 with viral peptides, as described by Madden et al. (48). Alteration of such secondary anchor positions which translate into T cell recognition differences have been reported (43, 44), however, in these previous studies T cell recognition differences were associated with changes in MHC binding and no specific rules were defined for the kinds of amino acid substitutions involved in obtaining higher activity analogs. It should be emphasized, however, that the enhanced T cell recognition of analogs identified in this study is not likely due to increases in MHC binding affinity since higher activity was associated with analogs with invariant or even decreased MHC binding affinity. Increased binding is likely to play an important role in the case of analogs where primary anchor positions have been optimized; however, in this study we purposely did not substitute primary MHC anchor residues. A recent study by Slansky (8) and colleagues has shed some light on the potential mechanism of heteroclicity. In their studies heteroclicity of the AH1 analogue of a H-2Ld-restricted gp70 tumor epitope was associated with an enhancement in the TCR binding affinity for the peptide-MHC complex compared with the cognate wild-type epitope and not to an increase in binding to the MHC molecule. When examined in more detail,
the enhanced TCR affinity of the AH1 analogue was not associated with changes in the main TCR contact residue or the main MHC contact residues at positions 2 and 9, suggesting that, similar to our findings, subtle changes in peptide structure may be contributing to heteroclicity. Some previous studies implied that modulation of T cell responses by heteroclitic analogs directly involve main TCR contact residues (6, 7, 49) but this finding is not corroborated by the current systematic analysis. In conclusion, our study suggests that heteroclitic analogs are most likely generated by subtle alterations in conformation rather than by gross alterations of TCR or MHC binding capacity.

It is of interest to compare our results with other published studies that have identified heteroclitic analogs for CTL. A heteroclitic analogue of a MART1/Melan A epitope has been shown to generate tumor-specific CTLs in vitro from PBMC of melanoma patients more efficiently than the wild-type peptide itself (12). Similarly, Schlom and colleagues (6) reported similar findings with a heteroclitic analogue of the CEA-derived CAP1 epitope although a side-by-side precursor frequency analysis or a TCR avidity analysis against wild-type peptide was not performed. More recently, Slansky (8) identified that a conservative substitution of valine to alanine at an odd-numbered position (position 5) in the wild-type gp70 epitope was associated with heteroclitic activity. Our current study extend their findings in several areas. First, although Slansky et al. reported that in vivo immunization with the AH1 analogue resulted in increases in CTL precursor frequency, their analysis was performed with in vitro stimulated cells where a potential for skewing the immune response exists. Herein, we have demonstrated that not only do heteroclitic analogs of p53.261 induce CTLs with higher avidity following in vivo immunization, they also induce a higher precursor frequency than wild-type peptide when measured without any in vitro manipulation of effector cells. Second, in studies reported herein we have defined some predictions for heteroclitic substitutions that is applicable for a wider array of HLA-A2.1-restricted epitopes and which have important implications in designing multi-epitope CTL vaccines for humans.

It should be noted that exceptions to the substitution patterns we describe in this study have been reported for heteroclitic analogs identified from other laboratories. For example, substitutions at position 1 for a MART1 epitope (12) and at position 6 for a CEA epitope (6) have resulted in heteroclitic activity. Thus, our predictions should not be taken as absolute rules but rather as a very efficient “shortcut” for predicting heteroclitic analogs. In this regard, current studies are ongoing to determine whether the substitution patterns identified for HLA-A2.1 are applicable for other HLA haplotypes.

Interestingly, the heteroclitic analogs identified in this study did not differentially regulate the production of Th1 or Th2 cytokines, as have been reported for other heteroclitic analogs (14). Our data suggests that heteroclitic analogs increase the production of both Th1 and Th2 cytokines by CTLs in terms of both a greater magnitude of cytokine production and more efficient stimulation at lower peptide doses. In fact, such overall stimulation by peptide analogs has been recently reported by some groups (49, 50). One possible explanation for the increases in both Th1 as well as Th2 cytokines from CTLs stimulated with heteroclitic analogs reported herein may be that CTL lines used in this study were predominantly of the Th0 phenotype whereas other studies showing differential cytokine responses may have used T cell clones or lines that were terminally differentiated.

Our findings have implications from the standpoint of vaccine development and clinical applications. First, through the application of our heteroclitic substitution rules, we increased the efficiency of detecting heteroclitic analogs from 2% (four identified from screening of 233 CEA.691 and MAGEA3.112 analogs) to 33% (three identified by screening of nine predicted p53.261 analogs). As a consequence, the labor intensive process of screening analogs for heteroclicity should be dramatically simplified thus making it more cost effective and amenable to high throughput. Second, we demonstrate that heteroclitic analogs are effective in raising polyclonal populations of specific T cells after in vivo immunization which may be more efficacious in resolving disease states in a clinical setting. Finally, the ability to generate high precursor frequencies of CTL possessing strong cross-reactive avidity against wild-type epitope may be important in instances where effective CTL responses against epitopes, normally tolerant to the immune system, are required.

It will be of interest, in future studies to examine to which degree this approach is applicable to other HLA-A and HLA-B alleles. As HLA-A2 is expressed in ~50% of the population and several different laboratories have already identified HLA-A2 restricted immunodominant epitopes of tumor antigens, our approach has immediate potential for increasing the activity of these HLA-A2 epitopes. While this approach may involve precise identification of HLA types and peptide epitopes, most of these procedures have now been simplified and automated. Thus, we believe that our approach has great potential in the field of immunotherapy of cancer and infectious disease in general.

We would like to thank Ajesh Maewal and Anthony Chiem for synthesis of peptides, and to Mingsheng Qin for technical assistance. We are also grateful to Robin Delp for secretarial assistance.

Supported in part by funds provided through National Institutes of Health-National Institute of Allergy and Infectious Diseases contract NO1-AI-95362.

Submitted: 25 April 2001
Revised: 28 June 2001
Accepted: 18 July 2001

References
1. Kag, D., and H. Hengartner. 1996. Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Curr. Opin. Immunol. 8:472–477.

844  Structural Features of Heteroclitic CTL Epitopes
2. Greenberg, P.D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. *Adv. Immunol.* 49:281–355.

3. Valmori, D., J.F. Fonteneau, C.M. Lizana, N. Gervois, D. Lienard, D. Rimoldi, V. Jingeneel, F. Joretue, J.C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. *J. Immunol.* 160:1750–1758.

4. Bakker, A.B., S.H. van der Burg, R.J. Huijbens, J.W. Drijfhout, C.J. Melfi, G.J. Adema, and C.G. Figdor. 1997. Analogues of CTL epitopes with improved MHC class I binding capacity elicit anti-melanoma CTL recognizing the wildtype epitope. *Int. J. Cancer.* 70:302–308.

5. Webster’s Ninth New Collegiate Dictionary. 1990. Merriam Webster Inc., Springfield, MA.

6. Zaremba, S., E. Barzaga, M. Zhu, N. Soares, K.Y. Tsang, and J. Schlom. 1997. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. *Cancer Res.* 57:4570–4577.

7. Loftus, D.J., P. Squarcina, M.B. Nielsen, C. Geisler, C. Castelli, N. Odum, E. Apella, G. Parmiani, and L. Rivoltini. 1998. Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T cell clones reactive to Melanoma/Melanocyte epitope MART-1. *Cancer Res.* 58: 2433–2439.

8. Slansky, E.J., M.F. Rattis, F.L. Boyd, T. Fahmy, M.E. Jaffee, P.J. Schnick, H.D. Margulies, and M.D. Pardoll. 2000. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. *Immunity.* 13:529–538.

9. Zugel, U., R. Wang, G. Shih, A. Sette, J. Alexander, and H.M. Grey. 1998. Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues. *J. Immunol.* 161:1705–1709.

10. Wang, R., Y. Wang-Zhu, C.R. Gabaglia, K. Kimachi, and H.M. Grey. 1999. The stimulation of low-affinity non-tolerized clones by heteroclitic antigen analogues causes the breaking of tolerance established to an immunodominant T cell epitope. *J. Exp. Med.* 190:983–994.

11. Men, Y., I. Micenon, D. Valmori, D. Rimoldi, J.C. Cerottini, and P. Romero. 1999. Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice. *J. Immunol.* 162:3566–3573.

12. Rivoltini, L., P. Squarcina, D.J. Loftus, C. Castelli, P. Tarzini, A. Mazzocchi, F. Rini, V. Viggiano, F. Belli, and G. Parmiani. 1999. A superagonist variant of peptide MART1/Melan A elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. *Cancer Res.* 59:301–306.

13. Tao, X., C. Grant, S. Constant, and K. Bottomly. 1997. Induction of IL-4 producing CD4+ T cells by antigenic peptides altered for TCR binding. *J. Immunol.* 158:4237–4244.

14. Salazar, E., S. Zaremba, P.A. Allen, K.Y. Tsang, and J.A. Schlom. 2000. Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of Tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. *Int. J. Cancer.* 85:829–838.

15. Nicholson, L.B., A.C. Anderson, and V.K. Kuchroo. 2000. Tuning T cell activation threshold and effector function with cross-reactive peptide ligands. *Int. Immunol.* 12:205–213.

16. Zitvogel, L., J.L. Mayordomo, T. Tjandrawan, A.B. DeLeo, M.R. Clarke, M.T. Lotze, and W.J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cell, B7 costimulation and T helper cell 1-associated cytokines. *J. Exp. Med.* 183:87–97.

17. Celluzzi, C.M., J.I. Mayordomo, W.J. Storkus, M.T. Lotze, and L.D. Faló, Jr. 1996. Peptide pulsed dendritic cells induce antigen specific CTL-mediated protective tumor immunity. *J. Exp. Med.* 183:283–287.

18. Romagnani, S. 1994. Lymphokine production by human T cells in disease states. *Annu. Rev. Immunol.* 12:227–257.

19. Selby, M., A. Erickson, C. Dong, S. Cooper, P. Parham, M. Houghton, and C.M. Walker. 1999. Hepatitis C virus envelope glycoprotein E1 originates in the endoplasmic reticulum and requires cytoplasmic processing for presentation by class I MHC molecules. *J. Immunol.* 162:669–676.

20. Skipper, J.C., R.C. Hendrickson, P.H. Gulden, V. Brichard, A. Van Pel, Y. Chen, J. Shabanowitz, T. Wolfel, C.L. Singluff, Jr., T. Boon, et al. 1996. An HLA-A2 tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel pathway for processing of membrane proteins. *J. Exp. Med.* 183:527–534.

21. Blake, J., J.V. Johnston, K.E. Hellstrom, H. Marquardt, and L. Chen. 1996. Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes. *J. Exp. Med.* 18:121–130.

22. Pinilla, C., R. Martin, B. Gran, J.R. Appel, C. Boggiano, D.B. Wilson, and R.A. Houghten. 1999. Exploring immunological specificity using synthetic peptide combinatorial libraries. *Curr. Opin. Immunol.* 11:193–202.

23. Boon, T., J.C. Cerottini, B. Van den Eynde, P. Van der Bruggen, and A. Van Vel. 1994. Tumor antigens recognized by T lymphocytes. *Annu. Rev. Immunol.* 12:337–365.

24. Gavin, M.A., B. Dere, A.G. Grandea, K.A. Hoggquist, and M.J. Bevan. 1994. Major histocompatibility complex class I allele-specific peptide libraries: Identification of peptides that mimic an H-Y T cell epitope. *Eur. J. Immunol.* 24:2124–2133.

25. Kawashima, I., V. Tsai, S. Southwood, K. Takesako, E. Celis, and A. Sette. 1998. The multi-epitope approach for immunotherapy of cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. *Hum. Immunol.* 59:1–14.

26. Ishioka, G.Y., J. Fikes, G. Hermanson, B. Livingston, C. Crimi, M. Qin, M.F. del Guercio, C. Dahlberg, J. Alexander, R.W. Chesnut, and A. Sette. 1999. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. *J. Immunol.* 162:3915–3925.

27. Ruppert, J., J. Sidney, E. Celis, R.T. Kubo, H.M. Grey, and A. Sette. 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. *Cell.* 74:929–937.

28. Dayhoff, M.O., R.M. Schwartz, and B.C. Orcutt. 1998. A model for evolutionary change. In Atlas of Protein Sequence and Structure, Vol. 5, Suppl. 3. M.O. Dayhoff, editor. National Biomedical Research Foundation, Washington, DC. 345–359.

29. Creighton, T.E. 1993. Proteins: Structures and Molecular Properties. 2nd ed. W.H. Freeman and Company, New York. 570 pp.

30. Cornette, J.L., K.B. Cease, H. Margalit, J.L. Spouge, J.A. Berzofsky, and C. DeLisi. 1987. Hydrophobicity scales and
computational techniques for detecting amphipathic structures in proteins. *J. Mol. Biol.* 195:659–685.

31. Kyte, J., and R.F. Doolittle. 1982. A simple method for displaying the hydrophatic character of a protein. *J. Mol. Biol.* 157:105–132.

32. Fauchere, J., and V. Pliska. 1983. Hydrophobic parameters pi of amino-acid side chains from the partitioning of N-acetyl-amino-acid amides. *Eur. J. Med. Chem.* 18:369–383.

33. Zamyatnin, A.A. 1984. Amino acid, peptide, and protein volume in solution. *Annu. Rev. Biophys. Bioeng.* 13:145–165.

34. Zamyatnin, A.A. 1972. Protein volume in solution. *Prog. Biophys. Mol. Biol.* 24:107–123.

35. Sette, A., J. Sidney, M.F. del Guercio, S. Southwood, J. Ruppert, C. Dahlberg, H.M. Grey, and R.T. Kubo. 1994. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. *Mol. Immunol.* 31:813–822.

36. Vitiello, A., D. Marchesini, J. Furze, L.A. Sherman, and R.W. Chesnut. 1991. Analysis of the HLA-restricted influenza specific cytotoxic T lymphocyte responses in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. *J. Exp. Med.* 173:1007–1015.

37. McKinney, D., R. Skvoretz, M. Qin, G. Ishioka, and A. Sette. 2000. Characterization of an in situ IFN-γ ELISA assay which is able to detect specific peptide responses from freshly isolated splenocytes induced by DNA minigene immunization. *J. Immunol. Methods.* 237:105–107.

38. Murali-Krishna, K., J.D. Altman, M. Suresh, D.J. Sourdive, A.J. Zajac, J.D. Miller, J. Slansky, and R. Ahmed. 1998. Counting antigen-specific CD8 T cells: a re-evaluation of bystander activation during viral infection. *Immunity.* 8:177–187.

39. Lewis, J.J., S. Janetzki, S. Schad, K.S. Panageas, S. Wang, L. Williams, L. Meyers, L. Butterworth, P.O. Livingston, P.B. Chapman, and A.N. Houghton. 2000. Evaluation of CD8+ T-cell frequencies by the ELISPOT assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. *Int. J. Cancer.* 87:391–398.

40. Visseren, M.J., S.H. van der Burg, E.I. van der Voort, R.M. Brandt, P.I. Schrier, P. van der Bruggen, T. Boon, C.J. Melfi, and W.M. Kast. 1997. Identification of HLA-A*0201 restricted CTL epitopes encoded by the tumor specific MAGE-2 gene product. *Int. J. Cancer.* 73:125–130.

41. Dyall, R., W.B. Bowne, L.W. Weber, J. LeMaault, P. Szabo, Y. Moroi, G. Piskun, J.J. Lewis, A.N. Houghton, and J. Nikolic-Zugic. 1998. Heteroclitic immunization induces tumor immunity. *J. Exp. Med.* 188:1553–1561.

42. Parkhurst, M.R., M.R. Salgaller, S. Southwood, P.F. Robbins, A. Sette, S.A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A201 binding residues. *J. Immunol.* 157:2539–2548.

43. Valmori, D., Gervois, N., D. Rimoldi, J.C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. *J. Immunol.* 160:1750–1758.

44. Davis, M.M., J.J. Boniface, Z. Reich, D. Lyons, J. Hampl, B. Arden, and Y. Chien. 1998. Ligand recognition by alpha beta T cell receptors. *Annu. Rev. Immunol.* 16:523–544.

45. Theobald, M., J. Biggs, D. Dittmer, A.J. Levine, and L.A. Sherman. 1995. Targeting p53 as a general tumor antigen. *Proc. Natl. Acad. Sci.* USA 92:11993–11997.

46. Theobald, M., J. Biggs, J. Hernandez, C. Labadé, and L.A. Sherman. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. *J. Exp. Med.* 185:833–841.

47. Madden, D.R. 1995. The three-dimensional structure of peptide-MHC complexes. *Annu. Rev. Immunol.* 13:587–622.

48. Madden, D.R., D.N. Garboczi, and D.C. Wiley. 1993. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. *Cell.* 75:693–708.

49. Dressel, A., J.L. Chin, A. Sette, R. Gausling, P. Hollenberg, and D.A. Hafler. 1997. Autoantigen recognition by human CD8 T cell clones. *J. Immunol.* 159:4943–4951.

50. Grakoui, A., D.L. Donermeyer, O. Kanagawa, K.M. Murphy, and P.M. Allen. 1999. TCR-independent pathways mediate the effects of antigen dose and altered peptide ligands on Th cell polarization. *J. Immunol.* 162:1923–1930.